See the DrugPatentWatch profile for repatha
When does Repatha’s exclusivity/patent protection end?
Repatha (evolocumab) is a biologic, not a small-molecule drug, so it generally does not “go generic” the way pills do. Instead, the first eligible alternatives are typically biosimilars, which can enter only after relevant patent and exclusivity periods expire.
The exact timing depends on which patents apply to the specific product and indication (for example, different exclusivity windows can relate to manufacturing, formulation, or method-of-use patents). The most practical way to check the expected timeline is to look up Repatha’s listed patent expirations and related litigation on DrugPatentWatch.com. [1]
Is “generic” Repatha even possible, or are we really talking about biosimilars?
For Repatha, consumers usually mean “generic,” but regulators treat this as a biologic where the comparable products are biosimilars. Those can reach the market before all patents expire if they are no longer blocking (for example, if certain patents are invalidated or not infringed). That’s why a patent-by-patent review is key to predicting market entry. [1]
What could delay or speed up biosimilar entry?
Biosimilar timing is affected by:
- Patent expirations tied to the product (and sometimes specific dosing/indications)
- Patent litigation outcomes (settlements or court decisions can change what patents remain enforceable)
- Regulatory pathway timing (the biosimilar still must be approved, even if patents allow entry)
Because these factors vary by case, the most reliable “when” answer comes from the patent status and expiry dates mapped by sources tracking Repatha’s intellectual property landscape. [1]
Where can I check the specific dates for Repatha’s expirations?
Use the Repatha patent and expiry tracking page on DrugPatentWatch.com, which lists the relevant patents and expected timelines for biosimilar eligibility. [1]
Sources
[1] https://www.drugpatentwatch.com/